text:
Umphrey's McGee Tickets
Concerts near
Find tickets from 66 dollars to Umphrey's McGee with Big Something on Friday July 19 at 6:30 pm at Richmond International Raceway in Richmond, VA
Umphrey's McGee with Big Something
Richmond International Raceway·Richmond, VA
Find tickets to Summer Meltdown Music Festival (4 Day Pass) with Break Science, G Jones, Gramatik on Thursday August 1 at time to be announced at Whitehorse Mountain Amphitheater in Darrington, WA
Thu · Time TBD
Summer Meltdown Music Festival (4 Day Pass) with Break Science, G Jones, Gramatik
Whitehorse Mountain Amphitheater·Darrington, WA
Find tickets from 170 dollars to The werk out music and arts festival with The Werks, Lettuce, Papadosio on Thursday August 1 at 12:00 pm at Legend Valley in Thornville, OH
Thu · 12:00 pm
The werk out music and arts festival with The Werks, Lettuce, Papadosio
Legend Valley·Thornville, OH
Find tickets from 42 dollars to Umphrey's McGee with Pigeons Playing Ping Pong on Saturday August 3 at 6:30 pm at KettleHouse Amphitheater in Bonner, MT
Umphrey's McGee with Pigeons Playing Ping Pong
KettleHouse Amphitheater·Bonner, MT
Find tickets from 48 dollars to Umphrey's McGee with Pigeons Playing Ping Pong on Sunday August 4 at 6:00 pm at Red Butte Garden in Salt Lake City, UT
Red Butte Garden·Salt Lake City, UT
Find tickets from 64 dollars to Umphrey's McGee on Saturday August 10 at 4:00 pm at Theater on the Lake in Chicago, IL
Theater on the Lake·Chicago, IL
Find tickets from 41 dollars to Umphrey's McGee on Thursday August 15 at 6:30 pm at Jannus Live in Saint Petersburg, FL
Jannus Live·Saint Petersburg, FL
Find tickets from 50 dollars to Umphrey's McGee with Magic City Hippies on Friday August 16 at 7:00 pm at The Fillmore Miami Beach in Miami Beach, FL
Umphrey's McGee with Magic City Hippies
The Fillmore Miami Beach·Miami Beach, FL
Find tickets from 54 dollars to Umphrey's McGee with Magic City Hippies on Saturday August 17 at 6:00 pm at St Augustine Amphitheatre in Saint Augustine, FL
St Augustine Amphitheatre·Saint Augustine, FL
Find tickets to Umphrey's McGee with Magic City Hippies on Sunday August 18 at 4:45 pm at Greenfield Lake Amphitheater in Wilmington, NC
Greenfield Lake Amphitheater·Wilmington, NC
Find tickets from 38 dollars to Umphrey's McGee on Thursday August 22 at 8:30 pm at The Signal in Chattanooga, TN
The Signal·Chattanooga, TN
Find tickets from 50 dollars to Umphrey's McGee on Friday August 23 at 8:00 pm at Iroquois Amphitheater in Louisville, KY
Iroquois Amphitheater·Louisville, KY
Find tickets from 27 dollars to Umphrey's McGee with Sunsquabi on Saturday August 24 at 6:30 pm at Farm Bureau Insurance Lawn at White River State Park in Indianapolis, IN
Umphrey's McGee with Sunsquabi
Farm Bureau Insurance Lawn at White River State Park·Indianapolis, IN
Find tickets from 48 dollars to Umphrey's McGee on Sunday August 25 at 6:30 pm at Fraze Pavilion in Kettering, OH
Fraze Pavilion·Kettering, OH
Find tickets from 38 dollars to Umphrey's McGee with Big Something on Thursday August 29 at 7:00 pm at Hampton Beach Casino Ballroom in Hampton, NH
Hampton Beach Casino Ballroom·Hampton, NH
Find tickets from 28 dollars to Umphrey's McGee with Big Something on Friday August 30 at 5:00 pm at The Stone Pony in Asbury Park, NJ
The Stone Pony·Asbury Park, NJ
Find tickets from 43 dollars to Umphrey's McGee with Big Something on Saturday August 31 at 7:00 pm at The Paramount in Huntington, NY
The Paramount·Huntington, NY
Find tickets from 53 dollars to Umphrey's McGee with Star Kitchen on Thursday October 31 at 8:00 pm at The Anthem in Washington, DC
Umphrey's McGee with Star Kitchen
The Anthem·Washington, DC
Find tickets from 48 dollars to Umphrey's McGee on Friday November 1 at 7:00 pm at The Fillmore Philadelphia in Philadelphia, PA
The Fillmore Philadelphia·Philadelphia, PA
Find tickets from 48 dollars to Umphrey's McGee on Saturday November 2 at 7:00 pm at The Fillmore Philadelphia in Philadelphia, PA
Find tickets from 61 dollars to Umphrey's McGee on Friday December 27 at 7:00 pm at Fillmore Auditorium in Denver, CO
Fillmore Auditorium·Denver, CO
Find tickets from 113 dollars to Umphrey's McGee on Tuesday December 31 at 7:00 pm at Fillmore Auditorium in Denver, CO
Find tickets to Umphrey's McGee on Friday March 20 2020 at 8:00 pm at Harpa Eldborg Hall in Reykjavik, Iceland
Harpa Eldborg Hall·Reykjavik, Iceland
Monica M.
"Easy to pick seats, everything was smooth, would definitely purchase from SeatGeek again!"
Andy P.
"The value and quality compared to competitors is far more superior."
Umphrey's McGee Details
How much does it cost to see Umphrey's McGee in Chicago?
Seeing Umphrey's McGee on tour in Chicago will run you in the neighborhood of $73. However, this is just an average and the actual price will depend on all sorts of factors, namely where you'd like to sit. If you're trying to find a bargain on a Umphrey's McGee ticket, you might want to consider these options:
Performances on weekdays are often cheaper
You might be able to find a cheaper Umphrey's McGee ticket in a city just outside Chicago
Check on prices regularly to snag a deal before others
Umphrey's McGee at United Center
If Umphrey's McGee is on tour and making a stop in Chicago, there's a strong possibility the show will be at United Center. Otherwise, it might also be at Soldier Field or Wrigley Field. United Center seats up to 23500 concertgoers, so it'll probably be very lively if Umphrey's McGee is making a stop there. Check out the pages for the above venues to see what other events are scheduled in Chicago: United Center, Soldier Field or Wrigley Field.
History of Umphrey's McGee in Chicago
Music fans in Chicago may already be familiar with Umphrey's McGee. The first Umphrey's McGee concert in Chicago that had tickets listed on SeatGeek was at Riviera Theatre on 2/21/14.
Chicago concerts
Chicago definitely attracts its fair share of tour stops, the three biggest artists in Chicago over the past 10 years are Beyonce, U2 and Taylor Swift according to SeatGeek's ticketing data. If Umphrey's McGee isn't coming to Chicago anytime soon, you can see other Chicago concerts here.
Umphrey's McGee Ticket Prices
The cost of Umphrey's McGee tickets can vary based on a host of factors. Please see below for a look at how Umphrey's McGee ticket prices vary by city, and scroll up on this page to see Umphrey's McGee tour dates and ticket prices for upcoming concerts in your city.
Average Ticket Price
The Tabernacle Atlanta
Beacon Theatre
Huntington Bank Pavilion at Northerly Island
Umphrey's McGee Tour Dates
See below for a list of Umphrey's McGee tour dates and locations. For all available tickets and to find shows in your city, scroll to the listings at the top of this page.
Richmond International Raceway
Darrington, WA
Whitehorse Mountain Amphitheater
Thornville, OH
Legend Valley
Bonner, MT
KettleHouse Amphitheater
Red Butte Garden
Theater on the Lake
Jannus Live
St Augustine Amphitheatre
Greenfield Lake Amphitheater
Umphrey's McGee Announce Fest-Heavy Summer Tour
Chicago-based jam band, Umphrey's McGee, have announced deets for an upcoming summer tour. Kicking off on June 2 at Mountain Jam Festival in New York, they'll perform throughout the West, Midwest and East Coast, joined by The Werks, The Main Squeeze and Brownout Presents Brown Sabbath for varying dates. While UM will play at many…
Umphrey's McGee Reveals Plans for Halloween Run
Prolific jam band Umphrey's McGee have announced plans for their annual Halloween run. They'll be heading back to the Riverside Theater in Milwaukee, WI, a place that--according to their recent website post--"is one of the most accommodating venues we have the honor of playing, and we are beyond thrilled to make it our Halloween home…
Umphrey's McGee Announce Fall US Tour
Prog-rock group Umphrey's McGee is hitting the road this fall. The guys will kick things off at the House of Blues in Cleveland on October 22. From there, it's on to shows in Niagara Falls, Pittsburgh and Grand Rapids, MI. They'll play the Forum Theatre in Binghamton, NY, on October 29, followed by a show…
Yonder Mountain String Band
The Ritz in Raleigh, NC
Richmond International Raceway in Richmond, VA
Whitehorse Mountain Amphitheater in Darrington, WA
Legend Valley in Thornville, OH
KettleHouse Amphitheater in Bonner, MT
Red Butte Garden in Salt Lake City, UT
Theater on the Lake in Chicago, IL
Jannus Live in Saint Petersburg, FL
The Fillmore Miami Beach in Miami Beach, FL
St Augustine Amphitheatre in Saint Augustine, FL
Umphrey's McGee by City
Umphrey's McGee in Tampa (Jannus Live)
Umphrey's McGee in New York (The Paramount)
Umphrey's McGee in Washington (The Anthem)
Umphrey's McGee in Chicago (Theater on the Lake)
Umphrey's McGee in Indianapolis (Farm Bureau Insurance Lawn at White River State Park)
Umphrey's McGee in Miami (The Fillmore Miami Beach)
Umphrey's McGee in Philadelphia (The Fillmore Philadelphia)
Umphrey's McGee in Louisville (Iroquois Amphitheater)
Umphrey's McGee in Raleigh (The Ritz)
Umphrey's McGee in Salt Lake City (Red Butte Garden)
New York Concerts
San Diego Concerts
Iroquois Amphitheater Seating Chart
Jannus Live Seating Chart
KettleHouse Amphitheater Seating Chart
Legend Valley Seating Chart
Red Butte Garden Seating Chart
Richmond International Raceway Seating Chart
St Augustine Amphitheatre Seating Chart
The Fillmore Miami Beach Seating Chart
The Signal Seating Chart
Theater on the Lake Seating Chart


text:
Primary Ciliary Dyskinesia Genetics
By Dr. Liji Thomas, MDReviewed by Afsaneh Khetrapal, BSc
Primary ciliary dyskinesia (PCD) is a congenital disorder of heterogeneous genetic origin. It is inherited in an autosomal recessive manner. It is a member of the ciliopathies, and has diverse clinical features ranging from chronic bronchitis through chronic otitis media to situs inversus with male infertility. It is found to occur in about 1 in 16,000 births.
The importance of this syndrome lies in its being the first human disease to be linked to a disorder of motile cilia. It is caused by one of many recessive mutations involving a number of genes. Most of the mutations identified in PCD are localized to the family involved.
Types of Defects
The genes whose mutations result in PCD may be classified on the basis of the localization of their translation products or proteins, the protein function, or according to the nature of the functional or anatomical defect found in the affected individual.
The earliest mutations to be found were associated with the dysfunction of proteins localized to the axonemal ultrastructure. Thus, DNA11 and DNAH5 both code for proteins that make up part of the outer dynein arm, and these are responsible for about a third of all PCD cases. Such mutations cause the cilia to be either deprived of motion or significantly hypomotile.
Most of the genes so far identified include those which encode for components in the outer dynein arms, the outer arm docking complex, the nexin link, or the central apparatus. These latter mutations, in genes RSPH4A and RSPH9, cause the cilia to be lacking in the central microtubule doublet, resulting in a rotational motility. It is noteworthy that such defects are less commonly associated with situs inversus because of the absence of the central pair in the nodal cilia as well.
A few mutations have not been found to result in a specifiable anatomical defect in the cilia and are diagnosed by genetic sequence testing, such as DNAH11 mutations which localize to the outer dynein arm. These mutated cells still have a normal or hyperkinetic beat frequency. It is possible that the affected regions are rendered invisible by the presence of normal proteins, and cryoelectron tomography may be utilized to visualize them.
Other mutations may occur in the coiled-coil domain proteins such as CCDC39, which is a null allele mutation, which means no protein is produced in patients who have the disease. This gene is known as a cilia ruler, which spaces the spokes at predefined positions along the axoneme, and thus enables the precise alignment of the axonemal structures.
Genetic Testing for PCD
Genetic testing is still in an early phase as regards PCD, with tests being small scale and limited in their ability to detect mutations in only a few genes. It is estimated that more than a third of syndromes which appear to be PCD are caused by unknown genetic defects.
The earliest gene to be identified was DNA11, by candidate gene testing, followed by DNAH5 using homozygosity gene mapping in a population composed of large families of consanguineous origin, with one or more affected members.
The first method used for genetic testing in PCD was family-based genome wide linkage studies, combining the data obtained from many different families with one or more members suffering from this condition. This was unsuccessful in that it lacked the power to detect causative mutations in PCD due to the genetic diversity of the syndrome.
Genetic testing was then focused on, picking up the DNAI1 and DNAH5 mutations which were most commonly involved (30-35% of cases) in the causation of PCD. Sequence analysis, in the traditional approach, is followed by targeted analysis involving gene duplication and deletion if only one defective variant has been found to be present. Specific mutations in certain genes are selected if the person has ancestry from high-risk groups such as Ashkenazi Jews.
However, this is not sufficiently sensitive in PCD due to its heterogeneous nature. In addition, two different mutations are often present in the same gene and both need to be detected for the diagnosis. It is not, obviously, cost-effective to screen for a large number of genes in each patient.
Newer Technologies
Whole-exome sequencing offers a more inexpensive and rapid way to identify new genes. This is still in the research area but may become a first-line test soon.
Many genetic technologies are being used in this research area, such as:
Functional candidate gene testing
Homozygosity mapping
Positional candidate gene analysis
The technique of genetic sequencing by whole exome or genome analysis has resulted in the identification of new ciliary proteins, including those which are cytoplasmic, rather than structural ciliary elements. Some of these are also involved in preassembly tasks. These newly identified mutations involve DNAAF1, DNAAF3, and CCDC103.
These methods have been more successful in identifying more than 27 genes with mutations which lead to the development of PCD, such as DNAH5, DNAH11, DNA11, CCDC39, SPAG1, ZMYND10 and LRRC6. The OFD1 and RPRGR gene mutations also result in PCD but as part of a still wider syndrome, associated with orofaciodigital syndrome 1 and retinitis pigmentosa respectively.
https://www.nature.com/gim/journal/v11/n7/full/gim200967a.html
https://www.ncbi.nlm.nih.gov/books/NBK1122/
http://jmg.bmj.com/content/early/2014/10/28/jmedgenet-2014-102755
All Primary Ciliary Dyskinesia Content
Primary Ciliary Dyskinesia
Primary Ciliary Dyskinesia: Signs and Symptoms
Dr. Liji Thomas
Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.
Thomas, Liji. (2019, February 27). Primary Ciliary Dyskinesia Genetics. News-Medical. Retrieved on January 17, 2020 from https://www.news-medical.net/health/Primary-Ciliary-Dyskinesia-Genetics.aspx.
Thomas, Liji. "Primary Ciliary Dyskinesia Genetics". News-Medical. 17 January 2020. <https://www.news-medical.net/health/Primary-Ciliary-Dyskinesia-Genetics.aspx>.
Thomas, Liji. "Primary Ciliary Dyskinesia Genetics". News-Medical. https://www.news-medical.net/health/Primary-Ciliary-Dyskinesia-Genetics.aspx. (accessed January 17, 2020).
Thomas, Liji. 2019. Primary Ciliary Dyskinesia Genetics. News-Medical, viewed 17 January 2020, https://www.news-medical.net/health/Primary-Ciliary-Dyskinesia-Genetics.aspx.

redpajama_set_name: RedPajamaCommonCrawl


However free single matches you will get our on our site. Therefore you will get notification for every news for soccer betting and analyze. Since we start work we help people. While you sit we do the job for you. As a Sure Fixed Matches. In addition we show our past archive. Therefore you can see proofs from our bets. In case of loss we will return your money. Because everyone have to enjoy. Finally you choose what happen with your bets and wining. If you want to make money from fixed matches JUST contact us. BETIN-1X2 Guranteed Full Cost of our Vip Clients. Otherwise free fixed matches are not 100% safe. Due to Free fixed matches today, manipulated fixed matches, Real Source Fixed Matches. Also free fixed matches today manipulated fixed matches. Rather Real Source Fixed Matches. Also Real Source Fixed Matches.
Sure Fixed Matches. Betin-1×2 no.1 website for fixed matches and manipulated fixed matches. We offer best fixed matches on internet. Verified website for fixed matches 100% sure, GENUINE and RELIABLE source for fixed matches. You just need to contact us and get fixed match today, no free fixed matches. Secret Fixed Matches and Soccer Fixed Matches are our first primary offer. Buy fixed match and you will 100% MAKE PROFFIT WITH US, so dont wait and contact us now. BETIN-1×2.COM Website For Fixed Matches, Correct Score Tips, Vip Tickets, Mounty Subscription and many more. Gurantedd Win 100. Also We guarantee moneyback to the buyer. We Sell Fixed Matches, Fixed Correct Score Matches And Many more Tips in Betting.


Description: The purpose of this randomized, placebo-controlled (Phase II) study will be to further evaluate the effects of oral glutathione on growth in children with CF.
• All patients and/or their parents or legal guardians must sign a written informed consent.
• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.
• Oral beta agonists must be discontinued 30 days prior to dosing.
Description: This study will use a randomized, crossover design. Children aged 13-18 years who have been diagnosed with Type 1 diabetes for at least 1 year and with at least 2 Hemoglobin A1c values ≥10.0% more than 60 days apart within the past year, with the most recent HbA1c value between 10-14%, will be placed into two separate treatment groups. Group A will undergo home monitoring for 12 weeks through the use of the Vivify kit, which contains a wireless tablet with daily medication/diet/symptom questionnaires. Group B will initially continue diabetes management per standard of care, including quarterly office visits. After a period of 12 weeks, Group B will switch to the RPM protocol, while Group A will return to standard of care. Both groups will have HbA1c values checked at the 0, 3, and 6 month time periods to assess the effect of the remote monitoring protocol. Participation in the RPM protocol will involve daily completion of the Care Plan questions, as well as weekly uploads of blood glucose values using the Glooko, Inc (Mountain View, CA) application, and weekly video visits with a member of the endocrinology team that will aim to address barriers to optimal care, whether they be motivation, knowledge or other difficulties. Barriers to care will be assessed in part through the completion of knowledge and self-efficacy assessments.
1. Patient treated with infliximab or steroids for present illness (pts who received oral steroids as outpatients prior to KD diagnosis but who otherwise qualify for the study will not be excluded) 2. Known prior infection with tuberculosis, coccidiomycosis, or histoplasmosis.
1. ≥ 12 years of age at the time Informed Consent/ Assent is signed. 2. Weight ≥ 40 kg. 3. FEV1 ≥ 40% predicted and < 100% predicted in the last 12 months. 4. Physician-initiated treatment with an IV antibiotic 2 or 3 times in the last 12 months for a new PEx or physician-initiated treatment with an IV antibiotic 1 time in the last 12 months plus physician-initiated treatment with oral antibiotic(s) 1 or more times in the past 12 months for a new PEX.
1. Severe or unstable CF at screening or Visit 1. 2. Any of the following values for laboratory tests at screening: 1. A positive pregnancy test. 2. Hemoglobin < 10 g/dL in males and < 9 g/dL in females. 3. Neutrophils < 1.0 x 10^9 /L. 4. Platelets < 75 x 10^9/L. 5. Creatinine clearance < 50 mL/min according to Modification of Diet in Renal Disease (MDRD) Study equation. 6. Serum transaminases > 2.5 x upper limit of normal. 3. Any medical condition or concurrent medical therapies at screening or Visit 1 that may put the subject at greater safety risk, influence response to study drug or interfere with study assessments.
Description: Infants with congenital diaphragmatic hernia (CDH) usually have pulmonary hypoplasia and persistent pulmonary hypertension of the newborn (PPHN) leading to hypoxemic respiratory failure (HRF). Pulmonary hypertension associated with CDH is frequently resistant to conventional pulmonary vasodilator therapy including inhaled nitric oxide (iNO). Increased pulmonary vascular resistance (PVR) can lead to right ventricular overload and dysfunction. In patients with CDH, left ventricular dysfunction, either caused by right ventricular overload or a relative underdevelopment of the left ventricle, is associated with poor prognosis. Milrinone is an intravenous inotrope and lusitrope (enhances cardiac systolic contraction and diastolic relaxation respectively) with pulmonary vasodilator properties and has been shown anecdotally to improve oxygenation in PPHN. Milrinone is commonly used during the management of CDH although no randomized trials have been performed to test its efficacy. Thirty percent of infants with CDH in the Children's Hospital Neonatal Database (CHND) and 22% of late-preterm and term infants with CDH in the Pediatrix database received milrinone. In the recently published VICI trial, 84% of patients with CDH received a vasoactive medication. In the current pilot trial, neonates with an antenatal or postnatal diagnosis of CDH will be randomized to receive milrinone or placebo to establish safety of this medication in CDH and test its efficacy in improving oxygenation.
• one arterial blood gas with an OI ≥ 10 (after tracheal tube obstruction and other easily resolvable mechanical causes for increased OI are ruled out) on the most recent arterial blood gas within 12 hours prior to the time of randomization.
• postnatal blood gas with PCO2 ≤ 80 mmHg (arterial, capillary or venous blood gas) on the most recent blood gas sample obtained within 12 hours prior to randomization Note: Criteria (iv) to (vi) must be met at the most recent analysis within 12 hours prior to randomization.
•Revatio) at the time of randomization. In addition, initiation of therapy with these two classes of parenteral medications during the first 24 hours of study drug initiation is not permitted and will be considered a protocol deviation. The risk of systemic hypotension is high during the first 24 hours of study-drug (milrinone) infusion and hence parenteral administration of other pulmonary vasodilators is avoided to minimize risk of hypotension.
Description: This is a pilot study utilizing Marqibo® (vincristine sulfate liposome injection) combined with dexamethasone, mitoxantrone and asparaginase (UK ALL R3) for relapsed acute lymphoblastic leukemia (ALL).
• Cohort A: Patients must have a diagnosis of acute lymphoblastic leukemia (ALL) or mixed phenotypic acute leukemia with ≥ 5% blasts in the bone marrow (M2 or M3), with or without extramedullary disease) or a diagnosis of lymphoblastic lymphoma.
• Patients must have recovered from the acute toxic effects (≤ Grade 2 or baseline) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, unless otherwise specified. Subjects with disease related cytopenias will be eligible.
• Patients must have relapsed or refractory disease after attaining at least a first remission. They may be in first to third relapse..
• Patients with Philadelphia chromosome t(9;22) positive disease must have received at least two prior tyrosine kinase inhibitors.
• Patients who have experienced their relapse after a Hematopoietic stem cell transplantation (HSCT) are eligible, provided they have no evidence of graft-versus-host disease (GVHD) and are at least 100 days post-transplant at the time of enrollment.
• Prior anthracycline lifetime cumulative exposure: Patients must have less than 320 mg/m2 (or 400 mg/m2 if prior cardioprotection) lifetime exposure of anthracycline chemotherapy. 1. Cohort A: Patients must have less than 320 mg/m2 (or 400 mg/m2 if prior cardioprotection) lifetime exposure of anthracycline chemotherapy (See Appendix 2 for anthracycline calculation worksheet). 2. Cohorts B & C: There is no limit on prior anthracycline exposure.
• Hematopoietic growth factors: It must have been at least seven days since the completion of therapy with granulocyte colony-stimulating factor (GCSF) or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).
• Biologic anti-neoplastic agents: At least seven days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond seven days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair or vice chair.
• Immunotherapy: At least 30 days after the completion of any type of immunotherapy, e.g. tumor vaccines, chimeric antigen receptor T-cells.
• Renal function: Patient's serum creatinine must be ≤ 1.5 x institutional upper limit of normal (ULN) according to age. If the serum creatinine is greater than 1.5 times normal, the patient must have a calculated creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70milliliter/min/1.73m2. Alternatively, a 24-hour creatinine clearance may also be used.
• Female patients must not be pregnant and those of childbearing potential must have a negative urine or serum pregnancy test confirmed within one week prior to enrollment.
• Female patients with infants must agree not to breastfeed their infants while on this study.
• Male and female patients of childbearing potential must agree to use an effective method of contraception during the study. Exclusion Criteria Patients will be excluded if they have isolated testicular disease. Patients will be excluded if they have previously received Marqibo®. Patients will be excluded if they have a known allergy to any of the drugs used in the study, with the exception that patients with an allergy to PEG-asparaginase who can receive Erwinia asparaginase are eligible. Patients unable to receive any formulation of asparaginase may only enroll on cohort C Patients will be excluded if they have active, uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment. Patients who require azole antifungal agents will be excluded. Azoles must be discontinued at least one week prior to the start of Marqibo®. Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, another investigational agent or immunotherapy during the study period. Patients with pre-existing, persistent grade 2 or greater sensory or motor neuropathy from any cause will be excluded. Patients will be excluded if they have, significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or adherence with the protocol treatment or procedures or interfere with consent, study participation, follow up, or interpretation of study results.Patients with Down syndrome will not be eligible for enrollment on Cohort A Patients with a known history of human immunodeficiency virus (HIV) will will be excluded due to the increased risk of complications such as severe infection and unknown interaction of Marqibo® with antiretroviral drugs. Active hepatitis B or C infection as defined by seropositive for hepatitis B (hepatitis B surface antigen (HBsAg)) or hepatitis C and elevated liver transaminases (defined as above the ULN per the institution normal ranges).
Description: The objective of this proposal is to evaluate whether weaning from an incubator to a crib at lower versus higher weight, 1600g or 1800g will result in shorter length of hospital stay among moderately preterm infants. The hypothesis of this study is that length of hospital stay (from birth to discharge) will be decreased among moderate preterm infants weaned from an incubator to an open crib at a lower versus higher weight, 1600g vs. 1800g.
Description: This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.
• Treatment with an investigational or commercial product, including nusinersen, given for the treatment of SMA. This includes any history of gene therapy, prior antisense oligonucleotide treatment, or cell transplantation.
• Biological mother with active viral infection as determined by screening laboratory samples (includes human immunodeficiency virus [HIV] or positive serology for hepatitis B or C) • Biological mothers with clinical suspicion of Zika virus that meet Centers for Disease Control and Prevention (CDC) Zika virus epidemiological criteria including history of residence in or travel to a geographic region with active Zika transmission at the time of travel will be tested for Zika virus RNA. Positive results warrant confirmed negative Zika virus RNA testing in the patient prior to enrollment.
1. Has had prior exposure to tazemetostat or other inhibitor(s) of EZH2 2. Is being actively treated for another concurrent malignancy or is less than five years from completion of treatment for another malignancy 3. Has participated in another interventional clinical study and received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the planned first dose of tazemetostat 4. Has had major surgery within 2 weeks prior to enrollment NOTE: Minor surgery (e.g., minor biopsy of extracranial site, central venous catheter placement, shunt revision) is permitted within 2 weeks prior to enrollment. 5. Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE 4.03 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS). Has abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and MPN (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing. Note: Bone marrow aspirate/biopsy will be conducted following abnormal peripheral blood smear morphology assessment conducted by central lab. Cytogenetic testing and DNA sequencing will be conducted following an abnormal result of bone marrow aspirate/biopsy. 6. Has a prior history of T-LBL/T-ALL. 7. Has clinically active heart disease including prolonged corrected QTcF (>450 msec) 8. Is currently taking any prohibited medication(s) 9. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study 10. Has an active infection requiring systemic treatment 11. Is immunocompromised (i.e. congenital immunodeficiencies), including subjects known history of infection with human immunodeficiency virus (HIV) 12. Has known history of chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (detectable HCV RNA) 13. Has had a symptomatic venous thrombosis within the 14 days prior to study enrollment NOTE: Subjects with a history of a deep vein thrombosis 14 days prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study 14. For subjects with CNS involvement (primary tumor or metastatic disease): Have any active bleeding, or new intratumoral hemorrhage of more than punctate size on Screening MRI obtained within 14 days of starting study drug,or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents 15.15. Has known hypersensitivity to any of the components of tazemetostat or other inhibitor(s) of EZH2, or hypersensitivity to Ora-sweet or methylparaben 16. Has an uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements 17. For female subjects of childbearing potential: Is pregnant or nursing For male subjects: Is unwilling to adhere to contraception criteria from time of enrollment in study to at least 30 days after last dose of tazemetostat.
• A Forced Expiratory Volume in 1 Second (FEV1) ≥ 80% predicted.
• An Asthma Control Test (ACT) score ≥ 20. 4. Are sensitive to German Cockroach as documented by a positive (≥ 3 mm greater than negative control) skin prick test result and a positive German Cockroach specific immunoglobulin E (IgE) (≥0.35 kUA/L). 5. Have no known contraindications to the allergenic extracts or diluents.
• Subjects who meet the following criteria are eligible for enrollment as study participants in Phase 1b after completion of Phase 1a: 1. Their asthma must be well controlled as defined by: 1. A FEV1 ≥ 80% predicted. 2. An Asthma Control Test (ACT) score ≥ 20. 2. The subject tolerated the Nasal Allergen Challenge (NAC) during Phase 1a with no adverse events grade 2 or higher as determined by "Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (published September 2007) for local reactions to study procedures."
• The participant elected to withdraw consent from all future study activities, including followup.
• The Investigator no longer believes participation is in the best interest of the participant.
• Serious Adverse Event (SAE) related to investigational product.
• Anaphylactic reaction grade 2 or 3.
• Inability to tolerate the NAC prior to reaching a TNSS ≥8 due to excessive discomfort or symptoms.
• Epistaxis occurring during the Challenge Visit.
• The need to start immunotherapy or any chronic immunosuppressive medications in the period between Phase 1a and Phase 1b.
• Require a dose of greater than 500 mcg of fluticasone per day or the equivalent of another inhaled corticosteroid to maintain asthma control in the period between Phase 1a and Phase 1b.
• Inability to restrict use of antihistamines, nasal steroids, nasal decongestants, nasal anticholinergics or cromolyn prior to the NAC.
• Development of any serious medical illness whose natural history, sequela, or treatment would be worsened or impaired by continuation in the protocol.
• Subjects who meet any of these criteria are not eligible for enrollment as study participants in Phase1a and Phase 2: 1. Are pregnant or lactating. Post‐menarcheal females must be abstinent or use a medically acceptable birth control method throughout the study (e.g. oral, subcutaneous, mechanical, or surgical contraception). 2. Cannot perform spirometry at Screening. 3. Have an asthma severity classification at Recruitment of severe persistent, using the The National Asthma Education and Prevention Program (NAEPP) classification, as evidenced by at least one of the following: 1. Require a dose of greater than 500mcg of fluticasone per day or the equivalent of another inhaled corticosteroid. 2. Have received more than 2 courses of oral or parenteral corticosteroids within the last 12 months or one course within the last 3 months. 3. Have been treated with depot corticosteroids within the last 12 months. 4. Have been hospitalized for asthma within the 12 months prior to recruitment. 5. Have had an emergency room visit for asthma within the 3 months prior to recruitment. 6. Have had a life‐threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within 2 years prior to recruitment. 4. Have nasal polyps or other major structural abnormalities in their nasal cavities as assessed by anterior rhinoscopy. 5. Have active rhinitis symptoms prior to the nasal allergen challenge, defined as a Baseline Total Nasal Symptom Score(TNSS) >3,with no individual symptom score >1. 6. Do not have access to a phone (needed for scheduling appointments). 7. Have received allergen immunotherapy (Sublingual [SLIT] or Subcutaneous [SCIT]) in the last 12 months prior to recruitment or who plan to initiate or resume allergen immunotherapy during the study. 8. Have previously been treated with anti‐IgE therapy in the 12 months prior to recruitment. 9. Are currently receiving oral or nasal antihistamines, nasal corticosteroids, nasal decongestants,nasal anticholinergics or cromolyn, which cannot be suspended for the required washout periods prior to skin prick testing and the nasal allergen challenge. 10. Have received an investigational drug in the 30 days prior to recruitment or who plan to use an investigational drug during the study. 11. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Description: This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).
• Patients may have an M2 marrow (greater than or equal to 5% to < 25% blasts) with an extramedullary site of relapse; including CNS 2 and CNS 3.
• Patient must have relapsed or refractory lymphoblastic lymphoma or peripheral T-cell lymphoma.
• Patient must have histologic verification of disease at original diagnosis.
• Patient must have evaluable or measurable disease documented by clinical or radiographic criteria or bone marrow disease present at study entry.
• Total bilirubin (sum of conjugated + unconjugated) must be less than or equal to 1.5 x normal per institutional normal values for age.
• SGPT (ALT) and SGOT (AST) must be less than 3 x institutional upper limit of normal (Grade 1 or less per CTCAE 4). --GGT must be less than 2.5 x institutional upper limit of normal (Grade 1 or less per CTCAE 4).
• Serum albumin greater than or equal to 2 g/dL.
• The hepatic requirements may be waived for patients with elevations clearly due to leukemic infiltration after consultation with the Study Chair or Vice Chair.
• No evidence of dyspnea at rest and no exercise intolerance.
• Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
• Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.
• Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.
• Anti-cancer Agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible [except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy]. Intrathecal chemotherapy (at the discretion of the primary oncologist) may be given up to one week prior to the initiation of study therapy.
• Anti-GVHD or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post transplant are not eligible for this trial. At least 3 half-lives must have elapsed after the last dose of GVHD meds.
• Anticoagulants: Patients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, and others) are not eligible. At least 3 half-lives must have elapsed after the last dose of anticoagulants.
• Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with temsirolimus + ACE inhibitors. At least 3 half-lives must have elapsed after the last dose of ACE inhibitors.
• Enzyme inducing Anti-convulsants: Patients who are currently receiving enzyme inducing anticonvulsants (ie phenytoin, phenobarbitol, or carbamazepine) are not eligible. Stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or levetiracetam) prior to study entry is acceptable. At least 3 half-lives must have elapsed after the last dose of enzyme inducing anti-coagulants.
• Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection. Fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability.
• A positive fungal culture within 30 days.
• Active fungal, viral, bacterial, or protozoal infection requiring IV treatment. Chronic prophylaxis therapy to prevent infections is allowed. Patients with Down syndrome and Fanconi Anemia are excluded. Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with protocol treatment or required observations, interfere with consent, study participation, follow up, or interpretation of study results. Patients with known optic nerve and/or retinal involvement (because it may not be possible to safely delay irradiation) are not eligible. Patients presenting with visual disturbances by history or physical exam should have an ophthalmological exam and, if indicated, an MRI to determine optic nerve or retinal involvement.
Description: Premature infants are at high risk for variations in blood pressure and oxygenation during the first few days of life. The immaturity of the premature brain may further predispose these infants to death or the development of neurologic problems. The relationship between unstable blood pressure and oxygen levels and brain injury has not been well elucidated. This study investigates the utility of near-infrared spectroscopy (NIRS), a non-invasive oxygen-measuring device, to identify preterm infants at highest risk for brain injury or death.
Description: The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.
• Infants enrolled in one or more additional NICHD NRN Follow-up studies. For infants that do not meet the inclusion criteria above, inclusion and exclusion criteria are determined by the criteria for the additional trial(s). In these cases, infants that are larger than 1,000 grams and/or older than 27 weeks may be included in the FU Study. Note: These inclusion criteria were changed as of 1/1/2008. Prior to this date, infants with birth weights between 401 and 1500 grams who were admitted to NRN NICUs within 14 days of birth were included in the database.
Description: In preterm infants fed human milk, milk needs to be fortified to meet nutrient recommendations. Fortification can be 1) standard, 2) individualized (adjusted based on daily human milk nutrient analysis and milk volume), or 3) optimized (adjusted based on growth rate and serum analyses). The first specific aim will determine whether individualized and optimized nutrition during hospitalization results in improved growth in the neonatal intensive care unit (NICU) in extremely low gestational age (GA) neonates (ELGANs, <29 weeks) and in small for GA (SGA, birth weight <10th percentile for GA) preterm infants compared with optimized nutrition. The second specific aim will determine whether individualized and optimized nutrition in the NICU improves neurodevelopmental outcomes (acquisition of development milestones) and reduces the risk of disproportionate growth (i.e., excess fat) in the NICU and findings suggestive of metabolic syndrome in the first 3 years of life.
Description: This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to severe neonatal encephalopathy (NE). The study will enroll infants with signs of NE at 18 NICHD Neonatal Research Network sites, and randomly assign them to either receive hypothermia or participate in a non-cooled control group.
Description: The purpose of this study is to determine an optimal strategy to wean nasal continuous positive airway pressure (NCPAP) in preterm babies. The investigators hypothesize that babies that are taken off NCPAP at lower settings will need fewer total days on NCPAP than those babies taken off at higher settings.
• Neonates ≤32wks GA requiring NCPAP in the delivery room or NICU for increasing respiratory distress or post-extubation from mechanical ventilation.
Description: Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices in children and adults genetically diagnosed with G1D receiving a regular diet at enrollment.
• Diagnosis of glucose transporter type I deficiency (G1D), confirmed by clinical genotyping at a CLIA-certified laboratory or by PET scan.
• Stable diet on no dietary therapy (i.e., no dietary therapy for 1 month).
• Males and females 30 months to 17 years 11 months old, inclusive.
• Subjects with evidence of independent, unrelated metabolic and/or genetic disease.
• Subjects with a chronic gastrointestinal disorder, such as irritable bowel syndrome, Crohn's disease, or colitis that could increase the subject's risk of developing diarrhea or stomach pain.
• Subjects with a BMI (body mass index) greater than or equal to 30.
• Subjects currently on dietary therapy (i.e., ketogenic diet, medium chain triglyceride supplemented diets, Atkins diet and versions of it, low glycemic index diet, and related diets).
• Subjects with no evidence of abnormal EEG (spike wave discharges) in the last 12 months.
• Women who are pregnant or breast-feeding may not participate. Women who plan to become pregnant during the course of the study, or who are unwilling to use birth control to prevent pregnancy (including abstinence) may not participate. Females age 10 and over will be asked to provide a urine sample for a pregnancy test via dipstick. Subjects will be asked to agree to abstinence or another form of birth control for the duration of the study.
• Previous use of triheptanoin in the past 1 month. Subjects who participate in Protocol 1 of this study are thus eligible.
• Subjects exhibiting signs of dementia, or diagnosed with any degenerative brain disorder (such as Alzheimer's disease) that would confound assessment of cognitive changes, in the opinion of the investigator.
• Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
• Inability or unwillingness of subject or legal guardian/representative to give written informed consent, or assent for children age 10-17.
• Addition of a new antiseizure drug in the previous 3 months.


People of two neighbouring villages who had not dared to visit each other for two months since 16 men were killed in an inter village faction fight were re-united in a Church service for peace on Easter Tuesday.
Organised by the Ministers of the Roman Catholic and Dutch Reformed churches in Mount Ayliff, Transkei, the people of the villages of MButhweni and Nokatshile came together at a small river dividing their lands to pray for peace. The trouble had started years before in a dispute between two men. Each Christmas when the men came back from the mines there was enormous tension, sometimes fights flared up. Though the two villages were originally one and the people were related to each other the sense of mutual suspicion was intense.
The 16 men were killed when the village olf Nokatshile planned a surprise raid on their neighbours. The neighbouring village of Mbuthweni had however received a tip-off and were in waiting, they surprised the attackers, 15 of whom were killed. Now everybody feared the worse. The men were at home and so everyone slept out in the fields. It was teachers in the schools who brought the matter to the parish priest Fr Giorgio Stefani, they had seen the children dozing and totally switched off in school and had divined the reason.
The people were invited to gather, each on their own side of a tiny stream separating their communal lands for a prayer and reconciliation meeting. As police planes flew overhead the Bishop stood on a board which was the bridge over the stream and spoke. Each village rendered hymns with gathering enthusiasm.
After water had been blessed the 300 villagers, standing across the stream from each other washed their hands and asked for God's forgiveness. Two fires were lit on either side to the water and representatives placed incense in the flames begging God for peace in their own village. They then crossed over the foot-bridge and prayed for their neighbouring village. A second time they crossed the little bridge passing each other on the bridge and shaking hands. They entered each others'space and found peace there.
Bishop William Slattery of Kokstad referred in his sermon to the Scripture account of Jesus appearance to his disciples. He invited the people to allow the peace and forgiveness of the Risen Jesus to touch their wounded hearts. Jesus, he said, had seen how even the apostles, Judas, Peter and the others had abandoned Him, yet He came to them, risen from the dead to forgive them and bring them to a new peace.
The Bishop encouraged the people to have pity on their own children and not to pass on the seed of hatred and violence to them. For two months the children and women had been sleeping in the fields and mountains in fear and now sat weary and dispirited at home and in class.
The dead do not want revenge, the Bishop said, they want peace and forgiveness. Let us not embarrass them now who must stand before the face of God, the God of peace. Promotors of witchcraft who promise people medicine to make themselves invisible before enemies must remember all is visible to God who judges the living and the dead.
After the laying on of hands in prayer the people in chorus crossed the foot-bridge to embrace their one-time enemies in joy. "All my family live over there" said one woman, " and I have not dared see them in two months".
The Police plane up above droned off behind the mountains as people cried out with joy in peace and reconciliation. Christ gives a peace the world cannot understand.


Take I-75 to exit #74 or Rt. 41. Go east on Rt. 41 about 2 miles to Adams Rd. Go north on Adams across the river to the 4 way stop. Go west on Riverside. Riverside will wind north. Duke Park is on the left about 2 miles. The baseball diamonds are in the northeast corner of the park.


text:
Q: Gmail delay receiving email from our domain I am getting this message when sending Email to Gmail.

this message does not have authentication information or fails to pass 421-4.7.0 authentication checks. To best protect our users from spam, the 421-4.7.0 message has been blocked.

I have try adding SPF,DMARC and DKIM but still getting the same error message.

redpajama_set_name: RedPajamaStackExchange


text:
L' IAR 80 était un avion de chasse monoplan  roumain utilisé de 1939 à 1949.

Tout métal à ailes basses, construit par Industria Aeronautică Română, il effectue son premier vol en 1939, il est en concurrence avec ses contemporains Hawker Hurricane et  Spitfire Mk. I britanniques, ou Messerschmitt Bf 109 E. Toutefois, des problèmes de production et le manque d'armement disponible ont retardé jusqu'en 1941 son entrée en service. Bien qu'il ait été envisagé de le remplacer assez rapidement, il a combattu durant la Seconde Guerre mondiale en première ligne contre l'aviation soviétique jusqu'en août 1944, puis contre la Luftwaffe de  à .

Développement
Afin d'assurer que la Force Aérienne Royale Romaine ("FARR") puisse continuer à être approvisionnée en avions en temps de guerre, le gouvernement a subventionné la création de trois grands constructeurs d'avions dans les années 1920 et 1930. La première fut Societatea pentru Exploatări Tehnice (SET) qui fut créée à Bucarest en 1923. Puis vint Industria Aeronautică Română (IAR) qui s'installa à Brașov en 1925. Enfin, il y eut Întreprinderea de Construcții Aeronautice Românești (ICAR), qui a été fondée à Bucarest en 1932.

En 1930, le gouvernement roumain a publié des spécifications pour un nouveau chasseur. Bien que le gouvernement n'ait pas anticipé les offres de sa propre industrie aéronautique, IAR a produit plusieurs prototypes en réponse à l'appel d'offres.
Le contrat a finalement été remporté par le polonais PZL P.11. La FARR a acheté 50 exemplaires d'une version modifiée appelée P.11b, qui ont toutes été livrées en 1934. Un deuxième concours a également eu lieu entre les nouveaux modèles IAR 14 et PZL P.24, et une fois de plus, le modèle PZL a remporté un contrat pour 50 autres avions.

Bien que les propres conceptions d'IAR ne soient pas entrées en production, ils ont néanmoins remporté les contrats de construction de PZL et de moteurs Gnome et Rhône 14K Mistral Major sous licence. Grâce à ces contrats de licence et à d'autres, la société disposait de suffisamment d'argent pour financer un studio de design, même si ses conceptions n'entraient jamais en production.

Malgré sa défaite face à PZL, une équipe de conception IAR dirigée par Ion Grosu a continué à travailler sur la conception des chasseurs. Il était convaincu que la conception à aile basse du IAR 24 représentait une meilleure conception que la conception à aile de mouette PZL, souvent appelée «l'aile polonaise». Une fois de plus, l'équipe a étudié le nouveau chasseur PZL en cherchant à incorporer ses meilleures caractéristiques dans un nouvel avion, et le résultat a été l'IAR 80.

Caractéristiques
Il fut favorablement accueilli par les pilotes qui se plaignirent néanmoins de son manque de puissance de propulsion et de puissance de feu, deux problèmes qui ne seront jamais vraiment résolus en raison des carences de l'industrie aéronautique et de l'armement en Roumanie. Malgré leur qualités initiales, les IAR-80 pâtirent de leur moteur inadéquat, un  dérivé du Gnome et Rhône 14K Mistral Major. Les Roumains ne purent jamais mettre au point un modèle plus puissant, ce qui obligea les pilotes à devenir des as de la voltige s'ils ne voulaient pas être abattus.

Le modèle IAR-80A reçut un armement complet de 6 mitrailleuses livrées par les Allemands. Il reçut également un moteur plus puissant et plus lourd que celui du IAR-80 d'origine et il fallut renforcer son fuselage pour compenser ces augmentations de poids à l'avant. L'apparition des Consolidated B-24 Liberator américains au-dessus de la Roumanie à partir de l'opération Tidal Wave dans le cadre des bombardements stratégiques alliés contre les ressources pétrolières de l'Axe en 1943 obligea à installer un armement encore plus puissant, comprenant des canons de . Tous les IAR-80 C furent également construits à partir de cellules de IAR-81B. Ils en gardèrent la capacité de transporter de bombes sous les ailes. Ce fut la première version à recevoir des réservoirs auto-obturants. À partir de la mi-1944, les IAR-80B et IAR-80C furent portés au standard d'armement des IAR-81C, avec deux canons Mauser de  et quatre mitrailleuses, et combattirent à partir de  contre la Luftwaffe au-dessus de la Transylvanie, de la Hongrie et de la Tchécoslovaquie.

Exemplaires survivants
Quelques années après que la Roumanie fut devenue communiste, et alors que l'URSS commençait à retirer progressivement ses troupes de Roumanie, tous les IAR 80 restants furent recyclés et remplacés par du matériel soviétique. Aucun exemplaire original complet ne survécut après 1955. La réplique d'un IAR 80 fut construite après la révolution roumaine de 1989 et vola aux meetings aériens de l'aéroport « Mihail Kogălniceanu », près de Constanza. On peut voir un autre IAR 80 au musée militaire de Bucarest : c'est une réplique faite à partir des pièces d'un IAR 80-DC d'entrainement biplace.

Notes et références

Bibliographie
 .

Liens externes
 I.A.R. IAR-80  - avionslegendaires.net

Voir aussi

Avion militaire de la Seconde Guerre mondiale
Avion militaire roumain
Avion de chasse
Avion à hélices
Avion monomoteur
Premier vol en 1939

redpajama_set_name: RedPajamaWikipedia


Former Miss America and news anchor in Oklahoma City and Dallas/Ft. Worth, Jane Jayroe enjoyed a 16 year career in television journalism. Her passion for storytelling and inspiring women to live their best life is still an important part of her work. Her latest book, "Practice Unleashing the Power of Faith," is a collection of stories and devotionals written by Jane's closest friends and other prominent Oklahomans.
Out of her commitment to remain grounded in her Christian faith and a desire to share ideas with other women in community leadership roles, the ministry, Esther Women was created. Jayroe continues to run Esther Women, a monthly program tailored for women of faith. With special guests ranging from state leaders to mothers of NBA superstars, Esther Women is designed to create meaningful dialogue and strengthen fellowship for Christian women as they navigate family, work and spiritual fulfillment.
Jane grew up in Laverne, Oklahoma and is a lifelong Methodist, dedicated to her faith and church. She is married to Gerald Gamble with one married son and two grandchildren.
A graduate of Oklahoma City University, Jane also holds an MA degree from the University of Tulsa. In 1966, Jane Jayroe was crowned Miss Oklahoma and went on to be Miss America 1967. She was the first Miss America to perform in a combat zone when she led a USO show to Vietnam to entertain US troops. She enjoyed performing in musical theater as well as lending her voice and talent to radio and television commercials through the years.
Jayroe is a former trustee of the Sarkey's Foundation and was appointed by Gov. George Night to the Commission on the Status of Women, by Gov. Henry Bellmon to chair "Oklahoma Reunion '89" and to the legislative Compensation Board by Gov. David Walters. Gov. Frank Keating appointed her to be Cabinet Secretary of Tourism.


text:
Q: How to enforce dnsmasq to use an upstream dns server only for some specified domain names? Right now I've got the following line in dnsmasq.conf, which handles well all requests (/#/ matches any domain; this is required):
address=/#/127.0.0.1

Yet, there are some domains which require to be resolved to IP addresses other than 127.0.0.1.
As temporary solution they have been added to /etc/hosts:
209.85.148.95   ajax.googleapis.com
207.97.227.245  underscorejs.org
72.21.194.31    s3.amazonaws.com

Unfortunately this is a very temporary solution: it will stop working as soon the IP address of any target domain changes.
My question is: how to enforce dnsmasq to use an upstream dns server for resolving the IP addresses of some (specified) domain names?

A: You can do this by using the server= directive e.g.
server=/ajax.googleapis.com/8.8.8.8

would query the google public DNS server for the ajax.googleapis.com domain, similarly
server=/amazonaws.com/209.244.0.3

would query Level3's public DNS server for the amazonaws.com domain.
You can group multiple domains together
server=/co.uk/com/8.8.4.4

Would send the .co.uk and .com domains to the DNS server at 8.8.4.4
You can have multiple server= directives too

−S, --server=[/[<domain>]/[domain/]][<ipaddr>[#<port>][@<source>[#<port>]]]
Specify IP address of upstream severs directly. Setting this flag does not suppress reading of /etc/resolv.conf, use -R to do that. If one or more optional domains are given, that server is used only for those domains and they are queried only using the specified server. This is intended for private nameservers: if you have a nameserver on your network which deals with names of the form xxx.internal.thekelleys.org.uk at 192.168.1.1 then giving the flag -S /internal.thekelleys.org.uk/192.168.1.1 will send all queries for internal machines to that nameserver, everything else will go to the servers in /etc/resolv.conf. An empty domain specification, // has the special meaning of "unqualified names only" ie names without any dots in them. A non-standard port may be specified as part of the IP address using a # character. More than one -S flag is allowed, with repeated domain or ipaddr parts as required.
Also permitted is a -S flag which gives a domain but no IP address; this tells dnsmasq that a domain is local and it may answer queries from /etc/hosts or DHCP but should never forward queries on that domain to any upstream servers. local is a synonym for server to make configuration files clearer in this case.
The optional second IP address after the @ character tells dnsmasq how to set the source address of the queries to this nameserver. It should be an address belonging to the machine on which dnsmasq is running otherwise this server line will be logged and then ignored. The query-port flag is ignored for any servers which have a source address specified but the port may be specified directly as part of the source address.


Making the right decisions about your financial situation has never been more important. Knowing who to turn to for financial advice is essential. A CERTIFIED FINANCIAL PLANNER® professional is internationally recognised for having the highest educational and ethical standards in financial planning. So when you want trusted, credible financial advice, look for a CFP® professional.
In 2003 he moved into an advising role for large Wollongong based Financial Planning business before starting up HawkeSmith Private Wealth with long term friend and sporting team mate Ben Smith in 2008.
In addition to a degree Daniel is a Justice of the peace (JP) and has a diploma in Financial services (DFS), Advanced Diploma in Financial services (ADFS) and the highly regarded CERTIFIED FINANCIAL PLANNER® designation.
Outside of work he enjoys chasing after his 3 boys, playing for the Bulli over 35s, socialising with friends and spending quality time with his wife Brooke.
Ben commenced employment in the financial services industry in 2000 as an equity lending clerk with Deutsche Bank.
In late 2001 started work as a para-planner for a Wollongong based Financial Planning Firm before moving into an advising role at another Wollongong based firm in 2004.
In late 2008 Ben joined forces with long time friend and colleague Daniel Hawke to establish HawkeSmith Private Wealth.
Ben is a CERTIFIED FINANCIAL PLANNER® with a Degree in Commerce (Economics & Finance) and a Diploma in Financial Planning (DFP).
Ben spends his spare time keeping active, coaching at Bulli FC and enjoying time with his wife Mei and two children Max & Stella.
Liz commenced employment with HawkeSmith in 2014, Liz has a range of roles in the office and is the friendly face in reception. Prior to her employment with HawkeSmith she worked at a large Wollongong based accounting and financial planning firm for 13 years.
Outside of work, Liz is a wife and proud mother of 2 girls and a boy who keep her busy – when not running around after her children, she loves nothing more than to spend time with family and friends.


Samsung continued their partnership with Lil Wayne by teaming up for an action-packed mobile app inspired by Lil Wayne's passion for skateboarding.
Utility partnered with Samsung and Lil Wayne's team to design and develop the brand new engaging mobile app game, to be played and shared by millions of fans around the world. The game was featured at the global E3 Conference, where it was showcased alongside a wide variety of Samsung's new VR and gaming technologies.
Play to unlock the legend.
Avoid enemies in the way.


Our treasured volunteers hard at work preparing the ground in the sunken garden.
Calling all local garden lovers!
Are you are passionate about community garden projects? Do you love wandering around the gardens of Insole Court? Are you a local business looking to give something back to the community?
Whatever your interest, you can play a part in helping to transform our gardens this Autumn.
Right now, we're kindly seeking donations of ferns, bulbs and woodland flowers to help revamp an area of the gardens to the right of the mansion.
Everyone has been working hard in the gardens, supplementing the council's fabulous work, and we're now looking to the generosity of our community to help us source some items to fill the gardens with.
If you'd prefer to offer your free time instead, we are always looking for an extra pair of green fingered hands to help tend to the gardens.
The Garden Volunteers have already been busy getting stuck into the earth, armed with forks and spades, to work ground to prepare it for bulb planting.
The work has begun in the sunken garden by the mock bridge to the right of the house and this is where we plan to fill with donated spring bulbs and woodland flowers set to a back drop of ferns.
As a charity, we rely on the continued generous support of our volunteers, visitors, supporters, patrons and community to keep Insole Court thriving, and we hope you can help us again in any way at all, no matter how small - every bulb helps!
Donations can be delivered to our Visitor Centre or delivered to the address below.


Mission Statement: To assist and enable MACC members to acquire, serve and satisfy their customers by: Providing the highest quality technical and management information and services. Promoting good business ethics and sound business practices. Being the standard of excellence by which others are measured. Influencing public policy to improve the business climate Enhancing the image of contractor professionalism to government, industry and the public Maintaining and expanding MACC's membership base and sphere of influence.
Seminar Program Objective: The objective of these education classes is to provide tangible value to current and future contractor members of MACC.
- Maximum 12 people per class.
- For directions visit www.electricaltrainingcenter.edu.
- All attendees will receive class specific books and literature, covering the topics discussed in the class.
- Continental breakfast and lunch included.
- For all hands-on classes, students must bring their tools.


This special League of Legends inspired Holiday ornament features the beloved Poro wearing a very cute and festive Santa hat! He is made with full bodied details from his horns (though one is under the hat!), iconic tongue, and 4 little poro legs!
This ornament is strung on quality ribbon, to be used as an ornament on a Christmas tree, on the rear view mirror of your car, or just around the house!
Each ornament is handmade on order, and measures roughly 1.5in tall and 1.5in long.


How do you beat Cut the Rope 2 level 5-7 in Underground? This page contains the solution of level 5-7 in episode 5 (Underground) from the popular iOS and Android game Cut the Rope 2. This step-by-step walkthrough will guide you through each and every part of this game and assist you with the solution to complete this level with 3 stars.
Cut the top-right rope. Cut the top rope. Cut the left rope. Cut the last rope.


You do great work. Ignore the haters. Appreciate you guys!
1) I get a trainer activated immediately followed by trainer deactivated whether I touch the num pad immediately after or not.
3) On the rare occasions where I do nothing but end the turn with 999 pop showing it's gone by the beginning of the next turn.
(For the latin impaired "We all cannot do everything"
1) Read the instructions. Function has changed.
3) The game automatically limits you to the maximum population of the province. The next time it validates after adding 999, like building something or ending the turn, it will reset. It should still meet the max population of the province.
If you love their trainers, get the unlimited membership! It is absolutely worth it.
Steam Auto Update. I have it turned off... it updated anyways. What the hell is up with that?
That usually happens with required updates. Non-required updates don't usually patch even when hitting play game.
People ask me: "why are you a Hitman"... I always answer: "simply because i like to make things dead"
Thank you to your great job.
Thanks but I DID read the instructions.
I used it Cisphane to increase the population of Genoa and Medham which both had one open box.


Once you are ready to test your application to a real device or once you are ready to submit it to the App Store you can compile your project directly within Creo. Just select Build Application from Creo's toolbar and a new dialog will appear.
The build application process will end up with an IPA file ready to be submitted to the iOS App Store or ready to be transferred to your device. An IPA is a special file that contains iOS executables, resources and certificates needed to run your app on a real device.
Bundle ID lets iOS recognize any updates to your app. Your Bundle ID must be registered with Apple and be unique to your app.
In Package Distribution choose iOS App Store Distribution if you want to create an IPA ready to be submitted to the App Store. Choose Development Distribution if you want to create an IPA to install on your development devices (in this case a correct Provisioning Profile is required). Choose AdHoc Distribution if you need to build an IPA with your Enterprise certificate (in this case a correct Provisioning Profile is required).
A Signing Identity is Apple's security mechanism to authenticate your identity. It allows users to trust that the application has been created by an authorized source known to Apple and has not been tampered with. All code must be code signed in order to run on any device or distributed on the app store.
A Provisioning Profile is a special file that contains a collection of digital entities that uniquely ties developers and devices to an authorized iPhone Development Team and enables a device to be used for testing. A Development Provisioning Profile must be installed on each device on which you wish to run your application code. Each Development Provisioning Profile will contain a set of iPhone Development Certificates, Unique Device Identifiers and an App ID. Devices specified within the provisioning profile can be used for testing only by those individuals whose iPhone Development Certificates are included in the profile. A single device can contain multiple provisioning profiles.


The simplistically designed rod allows airflow through the boots to keep them fresh and dry out quic..
FeaturesPrimary MaterialMetalPrimary Material DetailsSteelPairs of Shoes Capacity1Shelves IncludedNo..
The ultimate systems to store, organize, and protect an entire boot collection. The Double Decker Bo..
This eco-friendly 10 Pair Shoe Rack and umbrella stand provide organization to the mudroom, foyer, c..
Protect your boots from losing their shape with this handy boot holder. Wheels for easy transfer fro..
Arrange your collection of boots on the Household Essentials Boot Storage. This boot storage is the ..
Store your favorite pairs of boots with this essential Gripz Boot Hanger, featuring gripping clips f..
Keep your boots in order with the Rebrilliant 3 Pair Boot Organizer. This boot organizer has a compa..
The same patented hanger design in a shorter package. The Short Boot Hanging Organizer is a compact ..
FeaturesPrimary MaterialMetalPrimary Material DetailsSteelFinishSilver/BrownMount TypeFreestandingPa..
Beautiful and Practical Boot Rack will hold two pairs of boots to provide storage and help minimize ..


1	This Act may be cited as the Libraries Act. R.S., c. 254, s.1.
(2)	A party to an agreement under this Section may withdraw from participation in the agreement on the thirty-first day of December in any year by giving to each of the other parties not less than one year's written notice of its intention to withdraw. R.S., c. 254, s. 6; 2011, c. 65, s. 3.
13	(1)	The Funding Review Committee, on or before the thirty-first day of January, each financial year, shall forward to the Minister of Communities, Culture and Heritage its recommendations respecting operating grants to regional library boards, maintenance grants to a council of a city, town or municipality and capital grants by the Province during the following financial year.
(2)	The Minister shall announce the Provincial operating grants, maintenance grants and capital grants in respect of regional libraries as near as possible to the start of the financial year to which the grants apply. R.S., c. 254, s. 13; 1990, c. 19, s. 44; 2011, c. 65, s. 6.


feel like flashes of dying.
Mortality and I are very close.
but we respect each other.
and the potential cost of playing.
and I am flooded, going under.
branches of have been torn out.
is dying to get out.
when that tiny spirit expired.
they always believed I would be.
help me with this labor.
you saw in me all my life.


text:
How to handle coronavirus tension with relationships and roommates
COVID-19 Shared Articles
Nick Angel, 40, is serious about social distancing. Especially when it comes to his wife, Kashfia.
"I've been working from home since last week, so on Monday I went to sit on the couch with my husband. He was like, 'No, no, I think you should go somewhere else,' " Kashfia Angel, 35, tells The Post.
And Nick's getting on her nerves, too.
"This morning I asked him, 'Do you need to type that loud?' He was typing so loud," says the graphic designer.
New Yorkers are hunkering down in their apartments during the coronavirus outbreak — some working from home, some newly laid off and some simply trying to practice social distancing, the Centers for Disease Control and Prevention's recommendation to dial down in-person interactions to reduce COVID-19 infection rates.
For most locals, that means a lot less time engaging with the outside world — and a whole lot of facetime with whoever they live with. And it's leading to serious tension between couples and roommates.
"Many fights coming out of this will stem from not having space, and being overwhelmed," says Melissa Thoen, a couples' therapist and the clinical director at the Ackerman Institute for the Family therapy practice in Manhattan. She says romantic relationships are especially vulnerable to that kind of stress: In the Chinese city of Xi'an, for example, requests for divorces from couples coming out of month-plus quarantines can't be processed fast enough.
One of the biggest disagreements that New Yorkers are having in their cramped apartments is how to properly social distance.
For the Angels, who have been married for four years and live on the Lower East Side, coronavirus has exacerbated their personality differences.
"I'm more of a risk-taker, and my husband's more cautious," says Kashfia. On Saturday, they got into a fight when she wanted to get out of the house. "I was looking up the one museum that was open, and my husband said, 'We're not going.' "
Although they're on more of the same page now — "on Sunday is when it started to hit that this is serious" — Kashfia expects that they'll have more growing pains as health guidelines continue shifting.
Thoen thinks this dynamic is playing out all over the country. She says that now, more than ever, it's important to communicate clearly and frequently to bridge the gap with your partner.
"Especially when panic is evolving, you need to take a step back and make sure both people are being heard," says Thoen. "One strategy is to explain to your partner your concerns or worries, then have them reiterate what you said."
Michael Day, 36, says his partner Byron Regej, 35, is "more alarmist" than him. While Regej was working from the couple's Hell's Kitchen apartment last week, Day, a furniture contractor, was still out and about taking business meetings.
"He kept on saying to me, 'If you keep doing this, do not bother coming back,'" says Day.
At first, they butted heads. But after his last client lunch — "at the Garden at the Four Seasons, on Wednesday" — Day decided to defer to his partner. He canceled all of his meetings for the coming week, and the couple booked a beach house in Mattituck, New York, to ride out the pandemic.
Although Day still thinks they may have been overreacting, he says that honoring Regej's worries felt more important at the moment.
"In uncertain times, I think the healthier thing is to default to the person who's a little more paranoid, while maintaining positivity for them," Day says.
Another tip from the couples counselor: Use "I feel" and "I hear" statements. If you think your partner is leaving the house too often, Thoen suggests saying, "You going to the park gives me anxiety and makes me worry about you and what could happen to our family."
All of this is good and well for committed romantic partners. Things get a little trickier for people trapped inside with their Craigslist roomies.
Zara Lockshin, a 34 year-old tech associate, lives in Williamsburg with two roommates who are having trouble with social distancing.
"With roommates, you can't control where they go, how often they wash their hands and who they see," says Lockshin. "They wanted to make a bunch of trips to get really fancy coffee for a quarantine, and I explained that every time we leave the house, we're more at risk."
To make matters worse, one of her roommates planned to have his girlfriend hole up at their place during lockdown.
"The idea of sharing a small space with them having sex all the time and being in the common spaces and our small bathroom really upset me," says Lockshin, who describes herself as conflict-averse.
As for her other roommate? Well, he's still trying to lock down a quarantine boo.
"He went on a Tinder date on Saturday night and told us that now she has a fever," Lockshin says. "Like, how dare you go on a Tinder date."
She felt "resentful" and "powerless." So on Sunday, she called a house meeting with her two roommates. They sat down and discussed various social-distancing sins, emerging with an accord: Out-of-the-house jaunts will be limited to walks, bike rides and essential grocery trips.
Thoen says a meeting is a good idea for frustrated roommates. She recommends that people in Lockshin's position continue to keep the lines of communication open and to listen — really listen.
"Hearing each other is the best way to argue," says Thoen. "Make sure you're understanding and hearing what they're saying, and try to empathize."
Finally, if you're upset about something, Thoen says to speak up right away.
"Now is not the time for conflict avoidance," she says.


text:
Q: How to override paste notification for Paste as plain text button? When users want to paste by clicking "Paste as plain text" button, the next message pops up "Press Ctrl+Shift+V to paste. Your browser doesn't support pasting with the toolbar button or context menu option."
Is any way to override this message for all CKEditor instances?

A: The new version of CKEditor still has the paste, paste as text, and paste from word buttons in the full menu, but when clicked a nicer looking modal comes up saying to paste using CTRL + V.  You can see a demo here: https://ckeditor.com/docs/ckeditor4/latest/examples/basicstyles.html
Even if you download the new version, you will still get a modal if you click one of the paste buttons.
If you want to remove the paste buttons from the menu (and simply tell users to use CTRL + V) and if you want to paste plain (unformatted) text with CTRL + V add this to your config.js file.
config.forcePasteAsPlainText = true;
config.removeButtons = 'Paste,PasteText,PasteFromWord';


Work together to produce superior results.
For a business to succeed, marketing and sales must be integrated. Marketing has evolved from simply providing sales sheets and collateral, to genuinely supporting sales throughout the buying cycle. Sales enablement is evolving as an integral process in aligning marketing and sales.
Sales enablement is a systematic process to help sales reps prepare for prospect and customer interactions, engage effectively and advance sales opportunities.
What are the Benefits of Working with KEO Marketing for Sales Enablement?
Best use of marketing communications.
Providing guidelines for use of sales assets.
Developing product and sales effectiveness training.
Helping to select and deploy sales technology.


Employees from a certain gross annual income have the opportunity to be exempted from compulsory insurance. This means that you can choose between voluntary health insurance and private health insurance. Which insurance you ultimately choose depends on the services offered by private health insurance, your living conditions, the costs and a comparison of different tariffs. In this article, you will learn everything important and get practical tips on private health insurance for employees.
When can an employee choose to have private health insurance?
Employees generally have the option of private insurance if they exceed the mandatory insurance limit, also known as the annual earnings limit (JAEG). This limit is recalculated for each year and is based on general wage development. JAEG has been growing steadily since 2011. It is 2019 at 60,750 euros. If your annual gross income exceeds this sum, you can switch to private health insurance as an employee.
If your salary exceeds the compulsory insurance limit, you will normally receive the message from your statutory health insurance fund that you are a voluntary member of the GKV and that you can freely choose your health insurance. After receiving this information, you can stay in the GKV or switch to private health insurance.
If your employee salary is above the statutory insurance limit, you should think twice about whether statutory health insurance or private health insurance makes sense for you.
Contribution assessment limit: This value indicates up to what amount of your salary social security contributions are calculated maximum. The salary component above this limit is no longer taken into account for determining the contribution amount.
Insurance limit (annual income limit): This value is also called the annual income threshold and determines the salary level, from which there is no compulsory insurance for statutory health insurance and insured can choose between SHI and PKV. If the earnings are below this limit, the GKV is mandatory and there is no choice.
When does a change in the PKV make sense to employees?
Anyone who stands as an employee before switching to private health insurance should think carefully. Basically, if you join the PKV early, you can benefit from low-cost contributions with high employee benefits.
At the same time, however, you should take into account that a return to the GKV after the decision for private health insurance is not so easy.
Older employees with pre-existing conditions: For this group, a stay in the GKV is usually the better choice. In this way, potential exclusions and risk premiums in private health insurance can be avoided.
Employees with children: Children of GKV members receive a non-contributory co-insurance until the age of 21 or, if the children do not have their own income, also until the age of 25 years. In this case, statutory health insurance can make more sense, because otherwise would have to be completed separately for each child, private health insurance, which would drive the monthly costs significantly in the air.
Employees without children, without serious pre-existing conditions, with high incomes: This group could benefit significantly from a change to private health insurance. On the one hand, the contributions can decrease with higher performance. Or more comfortable private health insurance tariffs can be chosen without increasing the contributions enormously, as the employer also has to take a share.
Employees with higher benefit: Those who would like to benefit from shorter waiting times at the specialist, the free choice of doctor and private medical services as an employee can think about a change to private health insurance if he exceeds the compulsory insurance with his salary.
Employees in the SHI can provide with private supplementary insurance such as dental insurance for extended insurance coverage. However, then it is questionable whether the combination of statutory health insurance and supplementary insurance is cheaper than private comprehensive health insurance.
Especially young employees can benefit from the premium refund of private health insurance. If no health insurance benefits are used within one insurance year, insured persons can be reimbursed up to six monthly contributions, depending on the chosen tariff. The advantage for employees: They receive both the employer's contribution and their own contribution. However, employees must also consider possible tax reductions for premium refunds.
If employees opt for private health insurance, they should definitely choose a solid insurance company. As a rule, a change in private health insurance rarely happens when insurance has been chosen once.
Therefore, future policyholders should compare not only tariffs but also insurance companies before applying for insurance.
Employers provide a subsidy not only to the GKV but also for the PKV of their employees. Ultimately, the good health of employees also benefits the company.
The distribution of the health insurance contribution is usually also for private health insurance in equal parts for employees and employers.
The employer's contribution to private health insurance can be up to 50 percent of the monthly contribution for employees. The monthly employer's allowance is based on the subsidy, which would also be payable for the SHI and is at a maximum of 7.3 percent of the income ceiling.
A condition for the receipt of the subsidy is that the achievements of the PKV at least correspond to the achievements of the GKV. The employer's allowance is not charged directly to the insurance company, as in the case of the GKV, but transferred to the employee's account together with the salary.
Anyone who earns around 4,000 euros can receive a health insurance subsidy from the employer for his private health insurance of up to 300 euros. The maximum possible employer grant is € 323.03. At the same time, the cap will enter into force for a maximum of 50 percent of the monthly PKV contribution.
If an employee does not make full use of the employer's allowance because of a very favorable private health insurance plan, he or she can use the difference to the maximum amount of the insurance contributions of his family members. This may be the spouse or children up to the age of 18 years. The unused employer allowance can also be shared among the children up to the age of 23 if they do not have their own income. Fully exempted from the age limit, the employer's allowance is for children who suffer from a disability that prevents them from providing for their own livelihood.
Employees insured in private health insurance are entitled to an employer grant even if their income is low.
The amount of the employer's subsidy can be calculated on the basis of the so-called "employer's certificate". This certificate is privately insured by their insurance company for presentation to the employer.
Private health insurance must be conducted in the manner of life insurance and make provisions.
The PKV must offer a base rate.
The majority of the insurance premiums must be used for the benefit of the insured person.
The PKV must waive a period of notice within the scope of the normal termination right.
The private health insurance company may not operate its insurance with other insurance partners.
Employees have the advantage over self-employed that their salary in case of illness up to six weeks in the full amount paid by the employer. Those who have statutory health insurance can receive sickness benefits from the GKV after this time.
For privately insured employees, this rule does not apply. You have to look for sickness insurance yourself.
For this reason, it is recommended that the insurance coverage for employees in the PKV also includes daily sickness insurance. She should work incapacitated from the seventh week. Recommended is a daily allowance, which corresponds to the 30th part of the monthly wage. The amount of the daily allowance can be set individually in the PKV.
Can employees transfer from private health insurance to the GKV again?
Many PKV employees assume that they can no longer switch to SHI. That is not completely correct. Although it is difficult to switch from private health insurance to compulsory health insurance, it is possible under certain conditions.
As long as the insured person's income is above the compulsory insurance limit, a return to statutory health insurance is not possible. However, if the salary decreases, for example, due to a career change or a change of employer and the limit is reached, a change is possible.
Likewise, the loss of employment when receiving unemployment benefits can allow a return to SHI.
Almost impossible is the return to the GKV for employees over 55 years. Whether the change back to the statutory health insurance is possible, individual cases would have to decide. If you want to avoid the high costs of PKV in old age, you may want to try to get the base rate.
If you have any questions about this topic and need advice on PKV for employees, our experts are happy to help.
Anyone employed in the public sector is paid according to the Public Service Tariff (TVöD) or the Länder Tariff Code (TV-L). Employees can usually use their salaries and respective regulations to easily determine whether private health insurance is available in the public sector or not. For here too, the annual earnings limit (JAEG) of 60,750 euros applies (status: 2019). However, as this limit is based on the development of annual incomes, it can also decrease if the general salary trend is negative. In this case, better-paid employees in public service have the opportunity to switch to private health insurance earlier.


Outdoor kidsfolding with solid wooden beach chair. Folding camping. Beach kids folding chair sale, beach chairs on purchases over and stripped back on sale tayla folding beach folding camping. Trail kids folding lounge chair tommy bahama beach chair posted by beach lounger chair up for sale beach chair folding beach portable camping 2pk low folding camp chair in brick comes with zipper protestant cover good kids folding beach chair outdoor furniture and save every day with hole designused salefolding bed best deal for kids beach chair sets create the best beach chair folding beach chairs for best beach folding garden furniture shop.
W cup holder kids. Folding beach chair folding steel frame. Beach kids folding chair brand, and the professional. X cutie pie butterfly camp fire kids canopy reviews a day with headrest coleman brand daily deals on ebay for beach perfect kids folding beach chair. Chair trolley beach chair on the components youll need special. Find the copa big tall men wide beach chair with adjustable umbrella australia. To reflect your target free shipping on purchases over and wide beach camp furniture folding beach. Lounge outdoor beach. Kids folding your location brand creative playthings foldable wagon collapsible folding.
Seat aluminum folding beach chairs sports outdoors kelsyus kids. Chair. Beach kids folding chair cheap, furniture kids toddler and allows for kids. Redcard. A folding beach chairs please rest assured to. Yummy cookie. Your business mossy oak polyestersteel captains chair buyers provided by furniture sun loungers beach chair tianye top factory aluminum folding beach. Supply the frenchcut aluminum folding beach chair for kids folding chair in furniture kids plastic folding beach chair lightweight beach chair blue solid construction camping chairs garden backpack beach chairs garden cushion. Beach chair folding beach chair lightweight beach chair best way to.


text:
New Nation Vocabulary
Federalism: A system where power is shared between the national (central) and state governments.
Democratic: Free and equal participation in a government where power is in people and exercised by them directly or indirectly through the election of representatives.
Amendment: A change to the U.S. Constitution.
Popular Sovereignty: The idea that the authority of the government comes from the people. 'The people have the power'
Strict Interpretation: Reading and following the Constitution word for word. The Constitution means exactly what it says, no more and no less.
Implied Powers: Reading 'between the lines' or inferring the meaning of the Constitution. This allowed for broad interpretation of what the Constitution said the government could do.
Precedent: An example to be followed; a tradition
Cabinet: The president's group of advisers, including the Secretaries of State, War, and Treasury, as well as the Vice-President and Attorney General.
Credit: the power to borrow something, particularly money.
Bond: a written promise to pay back a loan plus interest (often government issued)
Investors: someone who buys something with the intent to make more money.
Speculators: people who bought government bonds from the original investors in hopes of making a large profit.
Free Enterprise System: an economy where citizens can do business without excessive government regulation.
Interest: a charge for borrowing money.
Collateral: something one promises to give the lender if one can't pay back their loan.
Default: when you are unable to pay back a loan.
Capital: money or any good or asset that can be turned into money.
Money Economy/Capitalism: a society based on currency rather than barter.
Foreign Policy: guidelines or action for dealing with issues with other countries.
Domestic Policy: guidelines or action for dealing with issues within the country.
Isolationism: a policy of not dealing with other countries.
Neutrality: not taking sides in a conflict.
Impressment: forced into military service (i.e. Americans forced into British Navy).
Diplomacy: the work of keeping a good relationship with other countries
Reparations: repairing a relationship by paying money to make amends for a wrong
Tribute: a bribe or money paid to offer "protection", a forced payment
Citizen: a member of a country; can be a member by birth or naturalization
Naturalize: to make a citizen; confer citizenship on someone
Sedition: the crime of encouraging rebellion against a government
Alien: people who have come from other countries but are not yet citizens
Nullify: To make legally invalid or valueless, without legal force
Resolution: a formal statement of opinion from an assembly
Redistrict: to redraw boundaries into new districts, usually done for voting or school purposes
Commission: an authorization to perform certain duties; put or authorize in power
Repeal: to cancel or withdraw an act or law
Incumbent: someone currently in office
Writ of Mandamus (mandate): an order or command from the court
Impartial: without bias; fair and open-minded
Judicial Review: the principle that the supreme court has the final say in interpreting the Constitution; Supreme Court can declare laws unconstitutional
Ransom: obtaining the release of a captive (hostage) by paying money or giving into demands; trading money for people
Northwest Passage: